Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Gastro-enteropancreatic neuroendocrine tumor × amino-acid, glucose, and electrolyte solution × Clear all

Phase

Phase 3 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Gastrointestinal 1 Endocrine 1

Conditions

Neuroendocrine Tumors 3 Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

pasireotide 2 Octreotide 2 Everolimus 2 lutetium Lu 177 dotatate 1 lanreotide 1 amino-acid, glucose, and electrolyte solution 1 Temozolomide 1 Sunitinib 1 Receptor-Like Protein Tyrosine Phosphatases, Class 2 1 Oxaliplatin 1 Leucovorin 1 Folfox protocol 1 Fluorouracil 1 Capecitabine 1 177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04919226 2025-09-10

COMPOSE

ITM Solucin GmbH

Phase 3 Active not recruiting

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡